Review ArticleClinical Review

Diastolic Heart Failure: A Review and Primary Care Perspective

Sean Haney, Denise Sur and Zijian Xu
The Journal of the American Board of Family Practice May 2005, 18 (3) 189-198; DOI: https://doi.org/10.3122/jabfm.18.3.189

References

  1. ↵
    O’Connel JB, Bristow MR. Economic impact of heart failure in the United States: time for a different approach. J Heart Lung Transplant 1994; 13: S107–12.
    OpenUrlPubMedWeb of Science
  2. ↵
    Litwin S, Grossman W. Diastolic dysfunction as a cause of heart failure. J Am Coll Cardiol 1993; 22: Suppl A 49A–55A.
  3. ↵
    Bonow RO, Udelson JE. Left ventricular diastolic dysfunction as a cause of congestive heart failure: mechanism and management. Ann Intern Med 1992; 117: 502–10.
  4. Zile M, Brutsaert D. New concepts in diastolic dysfunction and diastolic heart failure: part I: diagnosis, prognosis, and measurements of diastolic function. Circulation 2002; 105: 1387–93.
    OpenUrlFREE Full Text
  5. ↵
    Redfield MM, Jacobsen SJ, Burnett JC, et al. Burden of systolic and diastolic ventricular dysfunction in the community: appreciating the scope of the heart failure epidemic. JAMA 2003; 289: 194–202.
    OpenUrlCrossRefPubMedWeb of Science
  6. ↵
    Nishimura R, Tajik J. Evaluating diastolic filling of left ventricle in health and disease: Doppler echocardiography is the clinician’s Rosetta stone. J Am Coll Cardiol 1997; 30: 8–18.
    OpenUrlCrossRefPubMedWeb of Science
  7. ↵
    Thomas JT, Kelly RF, Thomas SJ, et. al. Utility of history, physical examination, electrocardiogram, and chest radiograph for differentiating normal from decreased systolic function in patients with heart failure. Am J Med 2002; 112: 437–45.
    OpenUrlCrossRefPubMedWeb of Science
  8. ↵
    Yusuf S, Pfeffer M, Swedberg K, et al. Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial. Lancet 2003; 362: 777–81.
    OpenUrlCrossRefPubMedWeb of Science
  9. ↵
    Senni M, Tribouilloy CM, Rodeheffer RJ, et al. Congestive heart failure in the community: a study of all incident cases in Olmsted County, Minnesota, in 1991. Circulation 1998; 98: 2282–9.
    OpenUrlAbstract/FREE Full Text
  10. ↵
    Kitzman DW, Gardin JM, Gottdiener JS, et al. Importance of heart failure with preserved systolic function in patients ≥65 years of age. Am J Cardiol 2001; 87: 413–9.
    OpenUrlCrossRefPubMedWeb of Science
  11. ↵
    MacCarthy PA, Kearney MT, Nolan J, et al. Prognosis in heart failure with preserved left ventricular systolic function: prospective cohort study. BMJ 2003; 327: 78–9.
    OpenUrlFREE Full Text
  12. ↵
    Vasan RS, Larson MG, Benjamin EJ, Evans JC, Reiss CK, Levy D. Congestive heart failure in subjects with normal versus reduced left ventricular ejection fraction: prevalence and mortality in a population-based cohort. J Am Coll Cardiol 1999; 33: 1948–55.
    OpenUrlCrossRefPubMedWeb of Science
  13. ↵
    Aurigemma GP, Gottdiener JS, Shemanski L, Gardin J, Kitzman DW. Predictive value of systolic and diastolic function for incident congestive heart failure in the elderly: the Cardiovascular Health Study. J Am Coll Cardiol 2001; 37: 1042–8.
    OpenUrlCrossRefPubMedWeb of Science
  14. ↵
    Devereux RB, Roman MJ, Liu JE, et al. Congestive heart failure despite normal left ventricular systolic function in population-based sample: the Strong Heart Study. Am J Cardiol 2000; 86: 1090–6.
    OpenUrlCrossRefPubMedWeb of Science
  15. ↵
    Kitzman DW, Little WC, Brubaker PH, et al. Pathophysiological characterization of isolated diastolic heart failure in comparison to systolic heart failure. JAMA 2002; 288: 2144–50.
    OpenUrlCrossRefPubMedWeb of Science
  16. ↵
    Philbin EF, Rocco TA, Lindenmuth NW, Ulrich K, Jenkins PL. Systolic versus diastolic heart failure in community practice: clinical features, outcomes, and the use of angiotensin-converting enzyme inhibitors. Am J Med 2000; 109: 605–13.
    OpenUrlCrossRefPubMedWeb of Science
  17. ↵
    Cohn J, Johnson G, Veterans Administration Cooperative Study Group. Heart failure with normal ejection fraction: the V-HeFT Study. Circulation 1990; 81: Suppl III 48–53.
  18. ↵
    Zile M, Brutsaert D. New concepts in diastolic dysfunction and diastolic heart failure: part II: causal mechanism and treatment. Circulation 2002; 105: 1503–8.
    OpenUrlFREE Full Text
  19. ↵
    Apstein CS, Morgan JP. Cellular mechanism underlying left ventricular diastolic failure. In: Gaasch WH, LeWinter MM, editors. Left ventricular diastolic dysfunction and heart failure. Philadelphia: Lea & Febiger; 1994. p. 3–24.
  20. ↵
    Cain BS, Meldrum DR, Joo KS, et al. Human SERCA2a levels correlate inversely with age in senescent human myocardium. J Am Coll Cardiol 1998; 32: 458–67.
    OpenUrlCrossRefPubMedWeb of Science
  21. ↵
    Slama M, Susic D, Varagic J, et al. Diastolic dysfunction in hypertension. Curr Opin Cardiol 2002; 17: 368–73.
    OpenUrlCrossRefPubMedWeb of Science
  22. ↵
    Lewis JF, Spirito P, Pelliccia A, Maron BJ. Usefulness of Doppler echocardiographic assessment of diastolic filling in distinguishing “athlete’s heart” from hypertrophic heart disease. Br Heart J 1992; 68: 296–300.
    OpenUrlAbstract/FREE Full Text
  23. ↵
    Zannad F, Dousset B, Alla F. Treatment of congestive heart failure: interfering the aldosterone-cardiac extracellular matrix relationship. Hypertension 2001; 38: 1227–32.
    OpenUrlAbstract/FREE Full Text
  24. ↵
    Brilla CG, Funck CR, Rupp H. Lisinopril-mediated regression of myocardial fibrosis in patients with hypertensive heart disease. Circulation 2000; 102: 1388–93.
    OpenUrlAbstract/FREE Full Text
  25. ↵
    Brustsaert DL, Fransen P, Andries LJ, De Keulener GW, Sys SU. Cardiac endothelium and myocardial function. Cardiovasc Res 1998; 38: 281–90.
    OpenUrlAbstract/FREE Full Text
  26. ↵
    Angeja B, Grossman W. Evaluation and management of diastolic heart failure. Circulation 2003; 107: 659–63.
    OpenUrlFREE Full Text
  27. ↵
    Dickstein K. Natriuretic peptides in detection of heart failure. Lancet 1998; 351: 4
    OpenUrlPubMedWeb of Science
  28. ↵
    Cowie M, Struthers A, Wood D, Coats A, Thompson S, Poole-Wilson P. Value of natriuretic peptides in assessment of patients with possible heart failure in primary care. Lancet 1997; 350: 1347–51.
  29. ↵
    Dao Q, Krishnaswamy P, Kazanerga R, Harrison A, Amirnovin R, Lenert L. Utility of B-type natriuretic peptide in the diagnosis of congestive heart failure in an urgent-care setting. J Am Coll Cardiol. 2001; 37: 379–85.
    OpenUrlCrossRefPubMedWeb of Science
  30. ↵
    Hunt SA, Baker DW, Chin MW, et al. ACC/AHA guidelines for the evaluation and management of chronic heart failure in the adult: executive summary. J Heart Lung Transplant 2001; 21: 189–203.
    OpenUrl
  31. ↵
    How to diagnose diastolic heart failure. European Study Group on Diastolic Heart Failure. Eur Heart J 1998; 19: 990–1003.
    OpenUrlFREE Full Text
  32. ↵
    Zile MR, Gaasch WH, Carroll JD, et al. Heart failure with a normal ejection fraction: is measurement of diastolic function necessary to make the diagnosis of diastolic heart failure? Circulation 2001; 104: 779–82
    OpenUrlAbstract/FREE Full Text
  33. ↵
    Kitzman DW. Heart failure with normal systolic function. Clin Geriatr Med 2000; 16: 489–512.
    OpenUrlCrossRefPubMedWeb of Science
  34. ↵
    Kitzman DW, Brudbaker PH, Anderson RA, et al. Exercise training improves aerobic capacity in elderly patients with diastolic heart failure: a randomized, controlled trial [abstract]. Circulation 1999; 100: 296
    OpenUrl
  35. ↵
    Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. The SOLVD Investigators. N Engl J Med 1991; 325: 293–302.
    OpenUrlCrossRefPubMedWeb of Science
  36. ↵
    Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). The CONSENSUS Trial Study Group. N Engl J Med 1987; 316: 1429–35.
    OpenUrlPubMedWeb of Science
  37. ↵
    Oren S, Grossman E, Frohlich ED. Reduction in left ventricular mass in patients with systemic hypertension treated with enalapril, lisinopril or fosenopril. Am J Cardiol 1996; 77: 93–6.
    OpenUrlCrossRefPubMed
  38. ↵
    Lorell BH. Cardiac renin-angiotensin system in cardiac hypertrophy and failure. In: Lorell BH, Grossman W, editors. Diastolic relaxation of the heart: the biology of diastole in health and disease, ed 2. Boston: Kluwer Academic Publishers; 1994. p. 91–100
  39. ↵
    Aronow WS, Kronzon I. Effect of enalapril on congestive heart failure treated with diuretics in elderly patients with prior myocardial infarction and normal left ventricular ejection fraction. Am J Cardiol 1993; 71: 602–4.
    OpenUrlCrossRefPubMedWeb of Science
  40. ↵
    Wachtell K, Bella JN, Rockkedal J, et al. Change in diastolic left ventricular filling after one year of antihypertensive treatment: the losartan intervention for endpoint reduction in hypertension (LIFE) study. Circulation 2002; 105: 1071–6.
    OpenUrlAbstract/FREE Full Text
  41. ↵
    Warner JG, Metzger DC, Kitzman DW, Wesley DJ, Little WC. Losartan improves exercise tolerance in patients with diastolic dysfunction and a hypertensive response to exercise. J Am Coll Cardiol 1999; 33: 1567–72.
    OpenUrlCrossRefPubMedWeb of Science
  42. ↵
    Andersson B, Caidahl K, di Lenarda A, et al. Changes in early and late diastolic filling patterns induced by long-term adrenergic β-blockade in patients with idiopathic dilated cardiomyopathy. Circulation 1996; 94: 673–82.
    OpenUrlAbstract/FREE Full Text
  43. ↵
    Bonow RO, Dilsizian V, Rosing DR, Maron BJ, Bacharach SL, Green MV. Verapamil-induced improvement in left ventricular diastolic filling and increased exercise tolerance in patients with hypertropic cardiomyopathy: short- and long-term effects. Circulation 1985; 72: 853–64.
    OpenUrlAbstract/FREE Full Text
  44. ↵
    Bonow RO, Leon MB, Rosing DR, et al. Effects of verapamil and propranolol on left ventricular systolic function and diastolic filling in patients with coronary artery disease: radionuclide angiographic studies at rest and during exercise. Circulation 1982; 65: 1337–50.
    OpenUrlAbstract/FREE Full Text
  45. ↵
    Udelson J, Bonow RO. Left ventricular diastolic function and calcium channel blockers in hypertrophic cardiomyopathy. In: Gaasch WH, LeWinter MM, editors. Left ventricular diastolic dysfunction and heart failure. Philadelphia: Lea & Febiger; 1994. p. 455–64.
  46. ↵
    Vasan RS, Benjamin EJ, Levy D. Congestive heart failure with normal left ventricular systolic function. Arch Intern Med 1996; 156: 146–56.
    OpenUrlCrossRefPubMedWeb of Science
  47. ↵
    Nagano R, Masuyama T, Lee JM, et al. Prediction of changes in cardiac output in association with preload reduction therapy in patient with hypertensive heart failure. Cardiovasc Drugs Ther 1997; 11: 49–56.
    OpenUrlCrossRefPubMedWeb of Science
  48. ↵
    Van Kraaij DJ, Jansen RW, Bouwels LH, Gribnau FW, Hoefnagels WH. Furosemide withdrawal in elderly heart failure patients with preserved left ventricular systolic function. Am J Cardiol 2000; 85: 1461–6.
    OpenUrlCrossRefPubMedWeb of Science
  49. ↵
    Pitt B, Zannad F, Remme WJ, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N Engl J Med 1999; 341: 709–17.
  50. ↵
    Grandi AM, Imperiale D, Santillo R, et al. Aldosterone antagonist improves diastolic function in essential hypertension. Hypertension 2002; 40: 647–52.
    OpenUrlAbstract/FREE Full Text
Back to top

In this issue

Print
Download PDF
Article Alerts
Email Article
Citation Tools

Jump to section